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ABSTRACT
Aim
Previous surveys have revealed wide variations in the 
management by radiation oncologists of non-small-
cell lung cancer (n s c l c ) in Canada. The aim of the 
present study was to determine the current patterns 
of practice for locally advanced and metastatic n s c l c  
among Canadian radiation oncologists.
Materials and Methods
An online survey was distributed electronically to 
all members of the Canadian Association of Radia-
tion Oncologists. Those who treat lung cancer were 
invited to participate. The survey consisted of three 
scenarios focusing on areas of n s c l c  treatment in 
which the radiotherapy (r t ) regimen that provides 
the best therapeutic ratio is unclear.
Results
Replies from 41 respondents were analyzed. For an 
asymptomatic patient with stage iiib n s c l c  unsuitable 
for radical treatment, 22% recommended immediate 
r t , and 78% recommended r t  only if the patient were 
to become symptomatic. Those who believed that 
immediate r t  prolongs survival were more likely to 
recommend it (p = 0.028). For a patient with a bulky 
stage iiib tumour and good performance status, 39% 
recommended palliative treatment, and 61% recom-
mended radical treatment (84% concurrent vs. 16% 
sequential chemoradiation at 60–66 Gy in 30–33 frac-
tions). Those who believed that chemoradiation has a 
greater impact on survival were more likely to recom-
mend it (p < 0.001). For a symptomatic patient with 
stage iv n s c l c , 54% recommended external-beam r t  
(e b r t ) alone, 41% recommended other modalities 
(brachytherapy, endobronchial therapy, or chemo-
therapy) with or without e b r t , and 5% recommended 
best supportive care. A majority (76%) prescribed 
20 Gy in 5 fractions for e b r t .
Conclusions
Compared with previous surveys, more radiation 
oncologists now offer radical treatment for locally 
advanced n s c l c . Management of n s c l c  in Canada 
may be evidence-based, but perception by radiation 
oncologists of the treatment’s impact on survival also 
influences treatment decisions.
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1.  INTRODUCTION
Lung cancer is one of the most common causes of 
cancer mortality in both men and women world-
wide 1. Most patients develop non-small-cell lung 
cancer (n s c l c ) and have either locally advanced or 
metastatic disease at presentation. Previous surveys 
conducted in 1993 and 1995 revealed wide varia-
tions in the treatment policies of Canadian radiation 
oncologists for n s c l c , and those surveys concluded 
that personal beliefs, rather than universal knowl-
edge, tended to guide the management of n s c l c   
in Canada 2,3.
In the 13 years since the more recent of the two 
surveys, the results of several randomized clinical 
trials focusing on palliative radiotherapy (r t ) for lo-
cally advanced and metastatic n s c l c  have been pub-
lished 4–12. However, the optimal dose, fractionation 
scheme, and timing for palliative r t  in n s c l c  remain 
controversial. The present study was undertaken to 
determine current patterns of practice across Canada 
for locally advanced and metastatic n s c l c  and to 
establish whether practice actually changed in the 
preceding decade.
The study survey consisted of three case sce-
narios designed to question radiation oncologists 
on areas of n s c l c  treatment in which the r t  regimen 
that provides the best therapeutic ratio is unclear 
(Table i).
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2.  MATERIALS AND METHODS
An online survey was distributed electronically to 
all active members of the Canadian Association of 
Radiation Oncologists (n = 274) in March 2007; those 
treating lung cancer were invited to participate. The 
study was approved by the Research Ethics Board at 
the University Health Network (Toronto, ON).
The initial page of the online survey required 
the explicit consent of study participants before the 
survey started. Respondents were presented with 
the three case scenarios listed in Table i. For each 
scenario, they were asked to specify the treatment 
regimen they would use, details pertaining to treat-
ment delivery, and the effect that the treatment might 
potentially have on patient survival. In addition, non-
identifying demographic information was solicited: 
the location and year in which respondents completed 
their specialty training, their current location and type 
of practice, and their level of experience in treating 
lung cancer. Finally, respondents were asked to rank 
the effect of each of the following factors on their 
treatment decisions: journals and books, seminars and 
meetings, practice guidelines, departmental policy, 
colleague preferences and expert opinions, personal 
experience, and availability of open clinical trials.
Responses were collected as either the single best 
answer or all applicable answers (chosen from menu op-
tions) and as free text. Percentages of respondents selecting 
a specific option were calculated. Statistical comparisons 
were made using contingency tables, generally with a 
chi-square test, using a Yates correction when required. 
When answer groups included fewer than 20 respondents 
or fewer than 5 events, the Fisher exact test was employed. 
Logistic regression was used to identify demographic 
factors associated with the treatment choice in each case. 
All tests of significance were two-sided, and differences 
were considered statistically significant at p values below 
0.05. The SPSS software application (version 14: SPSS, 
Chicago, IL, U.S.A.) was used for all analyses.
3.  RESULTS
3.1  Overview
Of the 46 responses collected, 41 were sufficiently 
complete and suitable for analysis; 5 were incomplete 
(>95% of questions unanswered) and were therefore 
excluded. This sample represented responses from 23 
of 37 Canadian cancer centres and from approximately 
30%–40% of the radiation oncologists treating lung 
cancer in Canada, based on a previous survey that 
identified 103 radiation oncologists treating lung cancer 
patients in Canada 13 and estimating that that number 
had grown by 10%–20% in the intervening period. 
All regions of the country were well represented. The 
distribution of respondents by centres showed 1 re-
spondent from each of 15 centres, 2 respondents from 
4 centres, 3 respondents from 1 centre, 4 respondents 
from 1 centre, and 5 respondents from 2 centres. Table ii 
summarizes demographic data for the respondents.
3.2  Scenario A: Asymptomatic Patient with Stage 
IIIB NSCLC Unsuitable for Radical Treatment
3.2.1  Radiotherapy Plan
For an asymptomatic patient with stage iiib n s c l c  
unsuitable for radical treatment, 22% of respondents 
t a b l e  i  Three case scenarios of non-small-cell lung cancer (n s c l c ) presented in the survey
Scenario A Should patients with locally advanced n s C l C  unsuitable for resection or radical radiotherapy, and with no or minimal 
thoracic symptoms, be given palliative radiotherapy (r t) immediately or as needed to treat symptoms?
An 80-year-old man with chronic obstructive pulmonary disease and chronic renal failure is found to have a 4-cm 
mass in the right upper lobe on routine chest radiograph. Biopsy of the mass confirms the diagnosis of squamous cell 
carcinoma (s c c ). Mediastinoscopy reveals bilateral mediastinal lymph node involvement with s c c . The rest of the 
metastatic workup is negative. Aside from fatigue, the patient has only a minor chronic cough, an Eastern Cooperative 
Oncology Group score of 2, and 14% weight loss within the past 6 months.
Scenario B Should patients with unresectable stage iii n s C l C  and large tumour volume be considered for radical treatment?
A 72-year-old previously healthy woman presents with a 2-week history of minor hemoptysis and no other symptoms. 
Her chest radiograph shows a 9-cm mass in the right upper lobe and associated partial atelectasis. Biopsy of the mass 
confirms the diagnosis of squamous cell carcinoma (s c c ). Mediastinoscopy reveals bilateral bulky mediastinal lymph 
node involvement with s c c , and the rest of the metastatic workup is negative. Her forced expiratory volume in 1 s is 
2 L (80% of predicted). She has mild fatigue, an Eastern Cooperative Oncology Group score of 1–2, and 3% weight 
loss within the past 3 months.
Scenario C For symptomatic patients with metastatic n s C l C , which dose–fractionation regimen is most appropriate?
A 70-year-old man presents with worsening dyspnea and no other symptoms. Computed tomography imaging of the 
chest shows a mass measuring approximately 4 cm and associated right middle lobe (r m l ) atelectasis. Bronchoscopy 
reveals the mass to be almost completely obstructing the r m l  bronchus, and biopsy of the mass confirms the diagnosis 
of squamous cell carcinoma. Bone scan shows 2 foci of metastatic deposits in the spine, which are asymptomatic. The 
patient has multiple co-morbidities, including diabetes and coronary artery disease, and has an Eastern Cooperative 
Oncology Group score of 2–3 and 12% weight loss within the past 6 months.35
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recommended immediate r t , and 78% recommended 
r t  only if the patient became symptomatic (Table iii). 
Of respondents choosing immediate r t , all but 1 
(89%) aimed to prevent symptoms (Table iv). In all 
instances, computed tomography (c t ) simulation 
was chosen. All respondents but 1 (89%) chose an 
anterior–posterior parallel pair (a p /p a ) plan over a 
three-dimensional (3D) conformal plan. Three dose 
fractionation schedules were prescribed: 20 Gy in 5 
fractions over 1 week (4 respondents); 30 Gy in 10 
fractions over 2 weeks (3 respondents); and 60 Gy in 
30 fractions over 6 weeks (1 respondent). One respon-
dent did not specify a dose–fractionation scheme. Half 
the respondents predicted that the average wait time 
for the start of r t  treatment (once the decision to treat 
was made) would be less than 1 week. Respondents in 
departments with wait times exceeding 1 week were 
more likely to chose a shorter fractionation schedule 
(p = 0.029).
3.2.2  Prognosis and Effect of Treatment
A majority of respondents (61%) estimated the median 
survival of the patient in scenario A to be 6–12 months 
(Table iv). Only 27% of the respondents believed 
that immediate r t  (versus delayed r t  until needed to 
treat symptoms) would prolong survival. Those who 
believed that immediate r t  would prolong survival 
were more likely to recommend it (p = 0.028).
3.3  Scenario B: Patient with Bulky, Unresectable 
Stage IIIB NSCLC and Good Performance Status
3.3.1  Radiotherapy Plan
For a patient with a bulky, stage iiib tumour and 
good performance status (p s), 39% of respondents 
recommended palliative treatment, and 61% recom-
mended radical treatment (Table iv). Most respon-
dents (76%) recommended combined chemoradia-
tion, and 20% recommended r t  alone (Table iii). 
Those who chose radical chemoradiation preferred 
a concurrent over a sequential approach (84% vs. 
16%). A dose range of 60–66 Gy in 30–33 fractions 
was prescribed by all respondents but 1 (who recom-
mended radical treatment, Table v). For palliative 
treatment, the most frequently prescribed dose was 
30 Gy in 10 fractions over 2 weeks. Overall, 54% 
of the respondents aimed to prolong survival; 37%, 
to relieve symptoms; 7%, to prevent symptoms; and 
2%, to “provide local control” (Table iv). Respon-
dents who aimed primarily to relieve symptoms 
selected a lower dose and a shorter fractionation 
schedule (p < 0.001). Simulation by c t  was chosen 
over fluoroscopic simulation by all respondents 
but 1. The most commonly chosen plan was a 3D 
conformal plan (56%), with 31% of the respondents 
electing to use an a p /p a  plan, and the remaining 13% 
choosing an oblique or other plan (unspecified). A 
majority of respondents (59%) predicted that the 
average wait time for starting r t  treatment would 
be 1–2 weeks.
3.3.2  Prognosis and Effect of Treatment
Of the survey respondents, 59% estimated the me-
dian survival of the patient in scenario B to be 6–12 
months (Table iv). A preponderance believed that 
treatment would prolong survival (88% stated that 
r t  would prolong survival, 64% that chemotherapy 
would, and 93% that chemoradiation would). Re-
spondents who recommended radical treatment or 
chemoradiation (as compared with those who did 
not) indicated a greater effect for chemoradiation on 
survival (p < 0.001).
t a b l e  ii  Characteristics of the survey respondents
Characteristic Respondents
(n) (%)
All respondents 41 100
Year specialty training completed
1970–1979 1 2
1980–1989 8 20
1990–1999 18 44
2000 and after 14 34
Location of specialty training
Canada 38 93
Britain 3 7
Fellowship training
Yes 28 68
No 13 32
Location of fellowship training
Canada 17 61
United States 7 25
Britain or Ireland 2 7
France 2 7
Years treating lung cancer
≤5 12 29
6–10 15 37
10–20 11 27
20–30 3 7
Locally advanced or metastatic n s c l c  cases annually
≤20 4 10
21–50 9 22
51–100 16 39
>100 12 29
Practice setting
University-affiliated 32 78
Community-based 9 22
Geographic location
Western Canada 9 22
Ontario 21 51
Quebec 6 15
Atlantic Canada 5 1236
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t a b l e  iii  Treatment recommendation for the case scenarios presented in Table i (N = 41)
Scenario Respondents
(n) (%)
Scenario A Asymptomatic stage iiib Immediate r t 9 22
Delayed r t 32 78
Scenario B Bulky stage iiib r t , then chemotherapy 4 10
Chemotherapy, then r t 5 12
Concurrent chemoradiation 22 54
r t  alone 8 20
Chemotherapy alone 1 2
Best supportive care 1 2
Scenario C Symptomatic stage iv e b r t 22 54
Brachytherapy 1 2
Brachytherapy, then e b r t 2 5
Endobronchial therapy, then e b r t 4 10
e b r t , then chemotherapy 10 24
Best supportive care 2 5
r t  = radiation therapy; e b r t  = external-beam r t .
3.4  Scenario C: Symptomatic Stage IV Patient with 
Poor Performance Status
3.4.1  Radiotherapy Plan
For a symptomatic patient with stage iv n s c l c , 54% 
recommended external-beam r t  (e b r t ) alone, 10% 
recommended endobronchial therapy followed by 
e b r t , 5% recommended brachytherapy followed by 
e b r t , 2% recommended brachytherapy alone, 24% 
recommended e b r t  followed by chemotherapy, and 
5% recommended best supportive care (Table iii). All 
respondents aimed to relieve symptoms. Most (82%) 
chose c t  simulation over fluoroscopic simulation 
(18%), and an a p /p a  plan (95%) over a 3D conformal 
plan (5%). Five dose–fractionation schedules for e b r t  
were prescribed (n = 38): 20 Gy in 5 fractions over 
1 week (76%); 30 Gy in 10 fractions over 2 weeks 
(13%); 36 Gy in 12 fractions over 2.5 weeks (8%); 
and 17 Gy in 2 fractions over 1 week (3%). Each 
respondent who chose brachytherapy prescribed a dif-
ferent dose: 8 Gy every week for 3 weeks, and single 
10-Gy and single 20-Gy fractions. Most respondents 
(79%) predicted that the average wait time for r t  
treatment start would be less than 1 week (Table iv). 
Respondents in departments with wait times exceed-
ing 1 week tended to chose a shorter fractionation 
schedule (p = 0.016).
3.4.2  Prognosis and Effect of Treatment
Most respondents (71%) estimated the median 
survival of the patient in scenario C to be less than 
6 months, and none felt that it would be longer than 
18 months (Table iv). Almost one third of the respon-
dents (32%) believed that r t  would prolong survival; 
66%, that chemotherapy would prolong survival; and 
51%, that chemoradiation would prolong survival. 
Respondents who recommended chemotherapy (as 
compared with those who did not) indicated a greater 
effect for chemotherapy on survival (p < 0.001).
3.5  Correlation with Demographic Factors
We also examined demographic factors of the respon-
dents possibly associated with treatment choice in 
each case: the year specialty training was completed, 
the location of residency or fellowship training, 
number of years dealing with lung cancer, location of 
practice, type of practice, and number of new n s c l c  
patients seen annually.
In scenario A, radiation oncologists in the com-
munity were more likely than those in university-affil-
iated centres to recommend immediate r t  (p = 0.011). 
In scenario B, radiation oncologists who had finished 
training more recently and those who saw more pa-
tients per year were more likely to recommend radical 
treatment (p = 0.017 and p = 0.010 respectively). We 
observed no correlations between treatment choice 
and demographic factors in scenario C.
When asked to rank the effect of 7 factors with 
respect to treatment decisions, 17 respondents chose 
practice guidelines as the most important, 9 chose 
availability of open clinical trials, 4 chose depart-
mental policy, 4 chose journals and books, 3 chose 
seminars and meetings, 3 chose personal experience, 
and 1 chose colleague preferences and expert opin-
ions. “Practice guidelines” were ranked by 80% of 
the respondents as one of the three most important 
factors influencing their treatment decisions; “per-
sonal experience” was ranked as one of the three most 
important factors by 52%.37
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4.  DISCUSSION
Palliative r t  regimens in advanced n s c l c  have been 
subject to rigorous evaluation in clinical trials 4–12,14. 
However, the way in which radiation oncologists in-
terpret the results of these trials influences their treat-
ment recommendations. The present study explored 
current patterns of practice for locally advanced and 
metastatic n s c l c  in Canada. Our survey had an es-
timated response rate of approximately 30%–40%. 
Although limited, our response rate is higher than 
that in other similar studies 15,16. A precise response 
rate cannot be provided, because it is difficult to 
t a b l e  iv  Management and perceptions for the three case scenarios presented in Table i
Variable Responses [n/N (%)]
Scenario A Scenario B Scenario C
Treatment intent
Radical n a 25/41 (61) n a
Palliative n a 16/41 (39) n a
Aim
Prolong survival — 22/41 (54) —
Prevent symptoms 8/9 (89) 3/41 (7) —
Relieve symptoms 1/9 (11) 15/41 (37) 41/41 (100)
Other — 1/41 (2) —
Estimated wait time from decision to r t  start (weeks)
>1 4/8 (50)a 5/39 (13) 8/39 (21)
1–2 3/8 (38) 23/39 (59) 16/39 (41)
2–4 1/8 (13) 10/39 (26) 14/39 (36)
>4 — 1/39 (3) 1/39 (3)
Median survival (months)
<6 11/41 (27) 12/41 (29) 29/41 (71)
6–12 25/41 (61) 24/41 (59) 11/41 (27)
12–18 4/41 (10) 4/41 (10) 1/41 (2)
>18 1/41 (2) 1/41 (2) —
Impact on median survival (months)
r t
None 30/41 (73) 5/39 (13)b 28/41 (68)
<3 7/41 (17) 24/39 (62) 12/41 (29)
3–6 4/41 (10) 10/39 (26) 1/41 (2)
Delayed r t
None 31/41 (78) n a n a
<3 8/41 (20) n a n a
3–6 1/41 (2) n a n a
Chemotherapy
None n a 14/39 (36)b 14/41 (34)
<3 n a 19/39 (49) 24/41 (59)
3–6 n a 6/39 (15) 3/41 (7)
Chemoradiation
None n a 3/41 (7) 20/41 (49)
<3 n a 9/41 (22) 16/41 (39)
3–6 n a 13/41 (32) 4/41 (10)
>6 16/41 (39) 1/41 (2)
a  No answer from 1 respondent.
b  No answer from 2 respondents.
r t  = radiation therapy.38
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determine the exact number of radiation oncologists 
who were treating lung cancer in Canada at the time 
of the survey. A better way to investigate patterns 
of practice across a nation is through practice audit; 
however, that approach is time consuming and often 
impractical. As a result, many studies, including ours, 
use survey data as a surrogate. One potential limita-
tion is that survey data may not accurately represent 
what is done in actual practice.
With advancements in technology, changes 
have occurred in how palliative r t  is delivered. Our 
survey confirmed these changes. In all three cases, 
c t  simulation was used by most respondents (82%–
100%). However, for “palliative” cases (scenarios A 
and C), a p /p a  was preferred over a conformal plan 
(89%–95%). That finding is consistent with an a p /p a  
plan being unlikely to exceed spinal cord tolerance 
for palliative cases, but not for radical cases.
For minimally symptomatic patients with un-
resectable n s c l c  not suitable for radical treatment 
(such as in scenario A), a randomized trial published 
in 2002 showed that immediate r t  does not improve 
symptom control, quality of life, or survival when 
compared with delay until symptoms require treat-
ment 17. The median survival of patients in this trial 
by Falk et al. were 8.3 months (immediate r t ) and 
7.9 months (delayed r t —most did not receive r t ). In 
our study, most respondents estimated the survival of 
the patient in scenario A to be 6–12 months, which 
agrees with the published results. Most respondents 
also believed that immediate r t  would not prolong 
survival, and 78% chose not to give r t  immediately 
and to treat only if the patient became symptomatic. 
When a similar case was presented in a survey con-
ducted in 1995, only 17% of the respondents chose 
no immediate active treatment 3. This change in the 
reported practice pattern may indeed be attributable 
to the published evidence. Increased use of chemo-
therapy may be a factor as well.
Scenario B is the most challenging scenario with 
respect to knowing the best evidence-based treatment. 
It was purposely designed to address a specific di-
lemma: What is the chance of cure for a patient with 
good p s, a bulky tumour, and no obvious metastases, 
if treated with radical chemoradiation rather than 
high-dose palliative r t ?
Several meta-analyses have shown that chemo-
radiation improves survival when compared with 
r t  alone for unresectable stage iii n s c l c  (absolute 
survival benefit of 2 months or 2% at 5 years) 18–20. 
However, the entry criteria for each trial differed, 
and the trials often do not explicitly state the tumour 
size, bulk, or intrathoracic disease deemed suitable 
for radical treatment. Most studies excluded patients 
based only on their blood work, pulmonary function, 
weight loss, and performance status (Eastern Coop-
erative Oncology Group score >1 or >2). The patient 
in scenario B certainly could have been an eligible 
candidate for randomized trials that investigated radi-
cal chemoradiation for unresectable stage iii n s c l c . In 
most of those trials, the median survival of patients 
with unresectable stage iii n s c l c  who received chemo-
radiation ranged from 10–18 months, compared with 
9–12 months with radiotherapy alone 18–20, and ap-
proximately 8 months with no immediate treatment 
(reported by Falk et al.) 17. The estimate of the respon-
dents concerning the effect of chemoradiation on sur-
vival for the patient in scenario B varied. However, as 
in scenario A, the estimate given by most respondents 
for the median survival of patient B without treatment 
agrees with the results in the existing literature and 
is also consistent with their estimates in scenario A. 
When a case similar to that of the patient in scenario B 
was presented in a previous survey in 1993 2, but 
with a much smaller tumour (4 cm compared with 
the 9 cm here) and a younger patient (59 years vs. 72 
years), only 31% of the respondents chose a radical 
approach. In contrast, 61% of the respondents in the 
present study chose a radical approach despite a much 
larger tumour (and thus likely a lower chance of cure), 
and more advanced patient age. Compared with past 
practice, the practice of today’s Canadian radiation 
oncologists has evolved to favour more aggressive 
treatment for n s c l c . However, whether this evolving 
practice is evidence-based is less clear.
Despite numerous studies examining various 
palliative dose–fractionation regimens, the optimal 
regimen for a symptomatic patient such the one de-
scribed in scenario C is not clearly established. The 
most recent Cochrane review concluded that most 
patients with locally advanced n s c l c  and thoracic 
symptoms should be treated with short courses of 
palliative r t , but selected patients with good p s should 
be considered for higher-dose palliative regimens—
for example, 36 Gy in 12 fractions) 14. Practice pat-
terns tend to be geographically based, and studies 
t a b l e  v  Radiotherapy dose and fractionation for the case presented 
as Scenario B in Table ia
Respondents Dose and fractionation Stated intent
(n) (Gy / fractions / weeks)
2 20 / 5 / 1 Palliative
7 30 / 10 / 2 Palliative
1 36 / 13 / 2.5 Palliative
2 40 / 15 / 3 Palliative
1 50 / 20 / 4 Palliative
1 50 / 25 / 5 Radical
11 60 / 30 / 6 1 Palliative
10 Radical
11 66 / 33 / 6.5 Radical
1 60–66 / 30–33 / 6–6.5 Radical
1 63 / 34 / 7 Radical
a Concurrent chemoradiation was chosen by 1 respondent, but the 
dose was not specified.39
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conducted by national groups often influence practice 
more than do studies undertaken elsewhere. The study 
most relevant to Canadians is the National Cancer 
Institute of Canada Clinical Trials Group s c.15 trial, in 
which 20 Gy in 5 fractions provided not only a similar 
degree of palliation of thoracic symptoms but also a 
2-month survival advantage as compared with a single 
fraction of 10 Gy 8. On post-hoc subgroup analysis, 
the improvement persisted only for patients who were 
p s 0–1 and had localized disease. Overall, patients 
who received 20 Gy in 5 fractions experienced sig-
nificantly greater improvement in symptoms related 
to lung cancer, pain, and ability to carry out normal 
activities and a better global quality of life.
In the present survey, for the patient in scenario C 
with a p s 2, most respondents (76%) prescribed 
20 Gy in 5 fractions using e b r t , and 71% of those 
who prescribed 20 Gy in 5 fractions believed that 
this regimen had no effect on survival, in keeping 
with results from the Canadian study. A majority of 
respondents (66%) also believed that chemotherapy 
had some effect on survival, and 24% chose e b r t  
followed by chemotherapy. Those numbers are simi-
lar to the numbers obtained in the previous survey 
(60% and 20% respectively). However, it is hard to 
make a direct comparison, because the patient in 
the present scenario is considerably older and has 
a poorer p s and more medical co-morbidities. For 
patients with a good p s, the meta-analysis from 1996 
showed that, as compared with best supportive care, 
chemotherapy is associated with improved quality 
of life and survival (5–7.5 months vs. 4 months) 19. 
This meta-analysis is being updated, and the benefit 
of chemotherapy is expected to be even greater now 
with third-generation regimens.
Data are also available to support the use of single-
agent chemotherapy in elderly patients, or patients 
with a p s of 2 21,22, but the evidence is not abundant for 
elderly patients with a p s of 2 because they are often 
underrepresented in clinical trials 23. In the present 
study, most respondents (71%) estimated the median 
survival of the patient in scenario C to be less than 
6 months, and they believed that chemotherapy would 
provide a survival benefit of less than 3 months, in 
keeping with the available evidence. Only 1 respon-
dent chose brachytherapy alone, because there is evi-
dence that high dose rate (h d r ) brachytherapy alone is 
less effective than e b r t  alone 24,25. Existing evidence 
does not conclusively indicate that h d r  brachytherapy 
and e b r t  would provide improved symptom relief 
over e b r t  alone, and only 2 respondents (5%) chose 
brachytherapy with e b r t  24.
Endobronchial therapy followed by e b r t  was 
chosen by 4 respondents (10%). Although the role of 
endobronchial therapy such as photodynamic therapy 
is not well defined, it can contribute to symptom relief. 
One randomized trial showed significant improve-
ment in the control of hemoptysis and the relief of 
dyspnea for patients receiving photodynamic therapy 
plus r t  as compared with those receiving r t  alone 26. 
For scenario C, most of the recommendations are in 
keeping with available evidence.
Overall, most Canadian radiation oncologists 
appear to practice evidence-based medicine, be-
cause their regimens are in agreement with results 
of several randomized studies. However, as in the 
preceding decade 3, the beliefs of the radiation on-
cologists about the treatment’s effect on survival 
still vary and also influence treatment decisions. For 
each scenario in the present study, radiation oncolo-
gists were more likely to recommend the treatment 
that they believed would have the greater impact on 
survival. Survival benefits may be overestimated by 
some of the respondents. The effect of the beliefs of 
the oncologists was also illustrated by Graham et 
al., who found that the attitudes of Ontario oncolo-
gists toward practice guidelines correlated with their 
intention to use those guidelines 27. Therefore, if 
strategies aiming to increase the uptake of evidence 
into practice are to be useful, they need to address 
those beliefs and perceptions.
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